Transplant Infectious Disease

Article	Citations
Clinical effectiveness of COVID‐19 vaccination in solid organ transplant recipients	89
Mucormycosis associated with COVID‐19 in two kidney transplant patients	51
Letermovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients	44
Outcomes of COVID‐19 in solid organ transplant recipients: A matched cohort study	43
Organ recovery from deceased donors with prior COVID‐19: A case series	42
Viruses, friends, and foes: The case of Torque Teno Virus and the net state of immunosuppression	40
Epidemiology, risk factors, and outcomes associated with cytomegalovirus in adult kidney transplant recipients: A systematic literature review of real‐world evidence	38
Impact of COVID‐19 in hematopoietic stem cell transplant recipients: A systematic review and meta‐analysis	35
Monoclonal antibody treatment for COVID‐19 in solid organ transplant recipients	35
Treatment of immunocompromised COVID‐19 patients with convalescent plasma	34
Mucormycosis in post‐COVID‐19 renal transplant patients: A lethal complication in follow‐up	32
Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild‐to‐moderate coronavirus disease 2019 during the Omicron epoch	29
Letermovir prophylaxis in solid organ transplant—Assessing CMV breakthrough and tacrolimus drug interaction	28
Hepatitis C‐positive donor to negative recipient kidney transplantation: A real‐world experience	27
Transplant of organs from donors with positive SARS‐CoV‐2 nucleic acid testing: A report from the organ procurement and transplantation network ad hoc disease transmission advisory committee	27
Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature	27
Antibody response to two doses of inactivated SARS‐CoV‐2 vaccine (CoronaVac) in kidney transplant recipients	26
An International survey on living kidney donation and transplant practices during the COVID‐19 pandemic	26
The pandemic provides a pathway: What we know and what we need to know about using COVID positive donors	26
Humoral and cellular response of COVID‐19 vaccine among solid organ transplant recipients: A systematic review and meta‐analysis	26
Feasibility and safety of remdesivir in SARS‐CoV2 infected renal transplant recipients: A retrospective cohort from a developing nation	24
Coronavirus disease 2019 vaccination is protective of clinical disease in solid organ transplant recipients	24
Clinical presentation and outcomes of COVID‐19 following hematopoietic cell transplantation and cellular therapy	23
Initial experience of bamlanivimab monotherapy use in solid organ transplant recipients	22
Treatment of invasive IMP‐4Enterobacter cloacaeinfection in transplant recipients using ceftazidime/avibactam with aztreonam: A case series and literature review	22

Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection	22
Is the Omicron variant truly less virulent in solid organ transplant recipients?	22
Humoral and cellular immune responses to the SARS‐CoV‐2 BNT162b2 vaccine among a cohort of solid organ transplant recipients and healthy controls	21
Successful liver transplantation in a patient recovered from COVID‐19	21
Infections after chimeric antigen receptor (CAR)‐T‐cell therapy for hematologic malignancies	21
Invasive pulmonary aspergillosis associated with COVID‐19 in a kidney transplant recipient	21
Cytomegalovirus in the transplant setting: Where are we now and what happens next? A report from the International CMV Symposium 2021	20
Breakthrough COVID‐19 after SARS‐CoV‐2 vaccination in solid organ transplant recipients: An analysis of symptomatic cases and monoclonal antibody therapy	20
Short‐term liver transplant outcomes from SARS‐CoV‐2 lower respiratory tract NAT positive donors	20
Cell‐free next‐generation sequencing impacts diagnosis and antimicrobial therapy in immunocompromised hosts: A retrospective study	20
Absolute lymphocyte count as marker of cytomegalovirus and allograft rejection: Is there a “Safe Corridor” after kidney transplantation?	20
Kidney transplantation from a SARS‐CoV‐2‐positive donor for the recipients with immunity after COVID‐19	19
Impact of donor multidrug‐resistant organisms on solid organ transplant recipient outcomes	19
Detection of adenovirus hepatitis and acute liver failure in allogeneic hematopoietic stem cell transplant patients	19
Post‐infection pulmonary sequelae after COVID‐19 among patients with lung transplantation	18
Clinical characteristics of COVID‐19 in solid organ transplant recipients following COVID‐19 vaccination: A multicenter case series	18
Successful heart and kidney transplantation from a deceased donor with PCR positive COVID‐19	18
Zoonotic sporotrichosis in renal transplant recipients from Rio de Janeiro, Brazil	18
Cytomegalovirus antiviral stewardship in solid organ transplant recipients: A new gold standard	17
Effect of immunosuppression maintenance in solid organ transplant recipients with COVID‐19: Systematic review and meta‐analysis	17
Early experience with SARs‐CoV‐2 mRNA vaccine breakthrough among kidney transplant recipients	16
Solid organ transplantation from COVID positive donors in the United States: Analysis of United Network for Organ Sharing database	16
Pregnancy after CMV infection following uterus transplantation: A case report from the Dallas Uterus Transplant Study	16
Evaluation of Quantiferon®‐Monitor as a biomarker of immunosuppression and predictor of infection in lung transplant recipients	16
A case report of successful kidney transplantation from a deceased donor with terminal COVID‐19‐related lung damage: Ongoing dilemma between discarding and accepting organs in COVID‐19 era!	16
Nocardia prophylaxis, treatment, and outcomes of infection in lung transplant recipients: A matched case‐control study	16
A retrospective matched cohort single‐center study evaluating outcomes of COVID‐19 and the impact of immunomodulation on COVID‐19‐related cytokine release syndrome in solid organ transplant recipients	16
Isavuconazole for the prophylaxis and treatment of invasive fungal disease: A single‐center experience	16
Letermovir conversion after valganciclovir treatment in cytomegalovirus high‐risk abdominal solid organ transplant recipients may promote development of cytomegalovirus‐specific cell mediated immunity	15
Eosinophilic gastroenteritis and graft‐versus‐host disease induced by transmission of Norovirus with fecal microbiota transplant	15
Kidney transplant recipients’ attitudes toward COVID‐19 vaccination and barriers and enablers to vaccine acceptance	15
Long‐term follow‐up of SARS‐CoV‐2 recovered renal transplant recipients: A single‐center experience from India	15
Risk factors of BK viral hemorrhagic cystitis in allogenic hematopoietic stem cell transplantation	15
Clinical characteristics and outcomes of toxoplasmosis among transplant recipients at two US academic medical centers	15
Phage therapy in a lung transplant recipient with cystic fibrosis infected with multidrug‐resistant Burkholderia multivorans	14
The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients	14
Incidence of herpes zoster in adult solid organ transplant recipients: A meta‐analysis and comprehensive review	14
Heart and liver transplant recipients from donor with positive SARS‐CoV‐2 RT‐PCR at time of transplantation	14
Antifungal stewardship in solid organ transplantation	13
The role of 18F‐Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) in assessment of complex invasive fungal disease and opportunistic co‐infections in patients with acute	13
Scedosporium apiospermum and Lomentospora prolificans in lung transplant patients – A single center experience over 24 years	13
Characteristics and outcomes among vaccinated lung transplant patients with breakthrough COVID‐19	13
COVID‐19 in a lung transplant recipient: Exploring the diagnostic role of circulating exosomes and the clinical impact of advanced immunosuppression	13
Treatment of asymptomatic bacteriuria in the first 2 months after kidney transplant: A controlled clinical trial	13
Sources and prevention of graft infection during long‐term ex situ liver perfusion	13
Assessment of humoral and cellular immune responses to SARS CoV‐2 vaccination (BNT162b2) in immunocompromised renal allograft recipients	13
Is it safe to perform abdominal transplantation from SARS‐CoV‐2 polymerase chain reaction positive donors?	12
De novo emergence of SARS‐CoV‐2 spike mutations in immunosuppressed patients	12
The outcomes of Clostridioides difficile infection in inpatient liver transplant population	12
Impact of solid organ transplant status on outcomes of hospitalized patients with COVID‐19 infection	12

Extended letermovir administration, beyond day 100, is effective for CMV prophylaxis in patients with graft versus host disease	12
Recurrent nocardiosis in solid organ transplant recipients: An evaluation of secondary prophylaxis	11
Immune reconstitution and severity of COVID‐19 among hematopoietic cell transplant recipients	11
Decreasing voriconazole requirement in a patient after extracorporeal membrane oxygenation discontinuation: A case report	11
Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole	11
Moving xenotransplantation from bench to bedside: Managing infectious risk	11
Incidence, etiology, risk factors, and outcomes of pre‐engraftment bloodstream infections after first and second allogeneic hematopoietic cell transplantation	11
Vaccine schedule recommendations and updates for patients with hematologic malignancy post‐hematopoietic cell transplant or CAR T‐cell therapy	11
Breakthrough invasive fungal infection after liver transplantation in patients on targeted antifungal prophylaxis: A prospective multicentre study	11
Infectious disease consultation is effective in boosting vaccine coverage in patients awaiting kidney transplantation: A French prospective study	11
Antibiotic allergy labels in immunocompromised populations	10
Rapid molecular detection of airway pathogens in lung transplant recipients	10
Short‐term kidney transplant outcomes from severe acute respiratory syndrome coronavirus 2 lower respiratory tract positive donors	10
Bronchial anastomosis dehiscence and stenosis caused by donor‐transmitted Mycoplasma hominis infection in a lung transplant recipient: Case report and literature review	10
Efficacy of β‐lactam/β‐lactamase inhibitors to treat extended‐spectrum beta‐lactamase‐producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients	10
SARS‐CoV‐2 infection after two doses of mRNA vaccine in renal transplant recipients	10
Donor‐derived tuberculosis among solid organ transplant recipients in the United States—2008 to 2018	10
Antibody response to mRNA SARS‐CoV‐2 vaccination in 182 patients after allogeneic hematopoietic cell transplantation	10
Risk factors and outcomes of COVID associated mucormycosis in kidney transplant recipients	10
Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Pre‐transplant predictors of survival, reactivation, and spontaneous clearance	10
Clinical decision making is improved by BioFire Pneumonia Plus in suspected lower respiratory tract infection after lung transplantation: Results of the prospective DBATE‐IT* study	10
Parvovirus B19 infection in pediatric allogeneic hematopoietic cell transplantation – Single‐center experience and review	10
Baloxavir treatment of oseltamivir‐resistant influenza A/H1pdm09 in two immunocompromised patients	9
COVID‐19 in lung transplant recipients: A single‐center experience	9
Favorable outcomes of COVID‐19 in vaccinated hematopoietic stem cell transplant recipients: A single‐center experience	9
Secondary antibody deficiency is associated with development of infection in kidney transplantation: Results of a multicenter study	9
A pragmatic outreach pilot to understand and overcome barriers to COVID‐19 vaccination in abdominal organ transplant	9
Real‐world effectiveness of preemptive therapy (PET) for cytomegalovirus (CMV) disease prevention in CMV high‐risk donor seropositive/recipient seronegative (D+R‐) liver transplant recipients (LTxR)	9
Perioperative antibiotic stewardship in the organ transplant setting	9
Usefulness of PCR for Trypanosoma cruzi DNA in blood and endomyocardial biopsies for detection of Chagas disease reactivation after heart transplantation: A comparative study	9
Hyperammonemia syndrome post‐lung transplantation: Case series and systematic review of literature	9
Diagnosis of central nervous system invasive aspergillosis in a liver transplant recipient using microbial cell‐free next generation DNA sequencing	9
The coverage of influenza and pneumococcal vaccination among kidney transplant recipients and waiting list patients: A cross‐sectional survey in Denmark	9
A case series of multidrug‐resistant tuberculosis in renal transplant recipients: Challenges in management from a TB endemic country	9
Gram‐negative bacteremia in solid organ transplant recipients: Clinical characteristics and outcomes as compared to immunocompetent non‐transplant recipients	9
Reinfection with SARS‐CoV‐2 in solid‐organ transplant recipients: Incidence density and convalescent immunity prior to reinfection	9
Bacterial genotype and clinical outcomes in solid organ transplant recipients with Staphylococcus aureus bacteremia	8
Management of ganciclovir resistance cytomegalovirus infection with CMV hyperimmune globulin and leflunomide in seven cardiothoracic transplant recipients and literature review	8
Comparison of standard versus low‐dose valganciclovir regimens for cytomegalovirus prophylaxis in high‐risk liver transplant recipients	8
Invasive aspergillosis in liver transplant recipients	8
Risk factor analysis for cytomegalovirus reactivation under prophylaxis with letermovir after allogeneic hematopoietic stem cell transplantation	8
Adoptive transfer of ex vivo expanded SARS‐CoV‐2‐specific cytotoxic lymphocytes: A viable strategy for COVID‐19 immunosuppressed patients?	8
Transmission of malaria from donors to solid organ transplant recipients: A case report and literature review	8
Cytomegalovirus events in high‐risk allogeneic hematopoietic‐cell transplantation patients who received letermovir prophylaxis	8
Early steps to kidney transplantation among persons with HIV and end‐stage renal disease in ESRD network 6	8
Association between gut colonization of vancomycin‐resistant enterococci and liver transplant outcomes	8
The hamletic dilemma of patients waiting for kidney transplantation during the COVID‐19 pandemic: To accept or not to accept (an organ offer)?	8
Evaluating clinical effectiveness of SARS‐CoV‐2 vaccine in solid organ transplant recipients: A propensity score matched analysis	8
The burden of cytomegalovirus infection remains high in high‐risk kidney transplant recipients despite six‐month valganciclovir prophylaxis	8
Early Clostridioides difficile infection characterizations, risks, and outcomes in allogeneic hematopoietic stem cell and solid organ transplant recipients	8
Neuroinvasive West Nile virus infection in solid organ transplant recipients	8
Clinical course of SARS‐CoV‐2 infection and recovery in lung transplant recipients	8
Antifungal prophylaxis in adult lung transplant recipients: Uncertainty despite 30 years of experience. A systematic review of the literature and network meta‐analysis	8
Epidemiology of candidemia in lung transplant recipients and risk factors for candidemia in the early posttransplant period in the absence of universal antifungal prophylaxis	8
Cytomegalovirus antiviral stewardship in the COVID‐19 Era: Increasing complexity of prophylaxis and treatment and potential mitigation strategies	8
Standardization of post‐operative antimicrobials reduced exposure while maintaining good outcomes in pediatric liver transplant recipients	8
Liver transplant evaluation for fulminant liver failure due to acute hepatitis A infection: Case series and literature review	8
Risk factors for progression from low level BK dnaemia to unfavorable outcomes after BK management via immunosuppressive reduction	8
Association between adenovirus infection and mortality outcome among pediatric patients after hematopoietic stem cell transplant	7
Neuroinvasive West Nile virus infections after solid organ transplantation: Single center experience and systematic review	7
COVID‐19 vaccination timing and kidney transplant waitlist management: An international perspective	7
Challenges and opportunities in stewardship among solid organ transplant recipients with Candida auris bloodstream infections	7
Clinical impact of multiple DNA virus infections in nondepleted haploidentical and unrelated allogeneic hematopoietic stem cell transplantation	7
Disparities in vaccination rates in solid organ transplant patients	7
Trimethoprim/sulfamethoxazole for nocardiosis in solid organ transplant recipients: Real‐life data from a multicentre retrospective study	7
Risk factors and clinical outcomes of tuberculosis among kidney transplant recipients in high endemic country	7
Incidence rate of active tuberculosis in solid organ transplant recipients: Data from a nationwide population cohort in a high‐endemic country	7
Kinetics of Torque Teno virus DNA in stools may predict occurrence of acute intestinal graft versus host disease early after allogeneic hematopoietic stem cell transplantation	7
Effectiveness of short vs long‐course perioperative antibiotics in lung transplant recipients with donor positive respiratory cultures	7
Association between cytomegalovirus infection and allograft rejection in a large contemporary cohort of heart transplant recipients	7
Cytomegalovirus nephritis in kidney transplant recipients: Epidemiology and outcomes of an uncommon diagnosis	7
Clinical risk score for predicting invasive fungal disease after allogeneic hematopoietic stem cell transplantation: Analysis of the China Assessment of Antifungal Therapy in Hematological Diseases (C	7
Progression of human monkeypox infection despite tecovirimat in an immunocompromised adult	7
SARS‐CoV‐2 vaccine clinical efficacy in SOT: What we know and our current gaps	7
Tuberculosis treatment without rifampin in kidney/kidney–pancreas transplantation: A case series report	7
Moderate acceptance of COVID‐19 vaccination in patients pre‐ and post‐heart transplantation: Experiences from a German Transplant Centre	7
Utility of deceased donor cultures in solid organ transplantation in preventing donor‐derived bacterial and fungal infectious diseases transmission	7
Successful management of T‐cell mediated rejection in a recent kidney transplant recipient with COVID‐19 associated severe acute respiratory syndrome	7
Epidemiology, risk factors, and association of antifungal prophylaxis on early invasive fungal infection in heart transplant recipients	7
The effectiveness and safety of low dose trimethoprim‐sulfamethoxazole for the treatment of pneumocystis pneumonia: A systematic review and meta‐analysis	7

Clearance of longstanding treatment‐resistant warts during COVID‐19 in a transplant recipient	7
Kinetics of torquetenovirus DNA load in a recent kidney transplant recipient with mild SARS‐CoV‐2 infection and a failed antibody response	7
“Saving lives with nirmatrelvir/ritonavir one transplant patient at a time”	7
Shorter is better: The case for short antibiotic courses for common infections in solid organ transplant recipients	7
Development and longevity of antibodies against SARS‐CoV‐2 in kidney transplant recipients after symptomatic COVID‐19	7
Live virus vaccination of pediatric solid organ transplant candidates within 1 month prior to transplantation: A multicenter experience	6
Successful treatment of CMV, EBV, and adenovirus tissue infection following HLA‐mismatched allogeneic stem cell transplant using infusion of third‐party T cells from multiple donors in addition to ant	6
Transplantation of organs from SARS‐CoV‐2‐positive donors: Preliminary experience from Spain	6
Cutaneous infection caused by paraconiothyrium cyclothyrioides in a renal transplant recipient	6
The role of chronic suppressive antibiotics therapy in superficial drive line infection relapse of left ventricular assist devices: A retrospective cohort from a tertiary care center	6
Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft‐versus‐host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Span	6
Role of cytomegalovirus specific cell‐mediated immunity in the monitoring of cytomegalovirus infection among living donor liver transplantation adult recipients: A single‐center experience	6
Post kidney transplant histoplasmosis: An under‐recognized diagnosis in India	6
Potential donor characteristics and decisions made by organ procurement organization staff: Results of a discrete choice experiment	6
Lung transplant recipient attitudes and beliefs on accepting an organ that is positive for hepatitis C virus	6
A multicenter evaluation of hepatitis B reactivation with and without antiviral prophylaxis after kidney transplantation	6
The impact of preservation fluid culture on graft site arteritis: A systematic review and meta‐analysis	6
COVID‐19 in a kidney transplant recipient after mRNA‐based SARS‐CoV‐2 vaccination	6
Clinical course of human monkeypox infection in a renal transplant recipient living with human immunodeficiency virus	6
Hypothermic oxygenated machine‐perfusion fluid‐related infection in a liver transplant recipient: First case report in the literature	6
Early administration of SARS‐CoV‐2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID‐19	6
Donor‐derived renal allograft mucormycosis in a combined liver and kidney transplantation: Case report and review of the literature	6
Survival after heart transplantation for Chagas cardiomyopathy using a conventional protocol: A 10‐year experience in a single center	6
Utility of methicillin‐resistant Staphylococcus aureus (MRSA) nasal screening in patients with acute myeloid leukemia (AML)	6
A split strategy to prevent cytomegalovirus after kidney transplantation using prophylaxis in serological high‐risk patients and a pre‐emptive strategy in intermediate‐risk patients: Combining the bes	6
A case report of tigecycline induced acute pancreatitis in a renal transplant patient and review of the literature: Should we avoid tigecycline in patients on calcineurin inhibitors?	6
Detection of human herpesvirus 6 DNA and chromosomal integration after allogeneic hematopoietic stem cell transplantation: A retrospective single center analysis	6
Donor‐derived herpes simplex virus hepatitis in a kidney transplant recipient and review of the literature	6
Human herpesvirus 6 reactivation in unmanipulated haploidentical hematopoietic stem cell transplantation predicts the occurrence of grade II to IV acute graft‐versus‐host disease	6
Detection of BK polyomavirus genotypes to predict the development of BK polyomavirus‐associated complications in kidney transplant recipients: A retrospective analysis	6
Primary sclerosing cholangitis as an independent risk factor for cytomegalovirus infection after liver transplant	6
Incidence, risk factors, outcomes, and clinical management of BK viremia in the modern era of kidney transplantation	6
Risks and outcomes of adenovirus disease in pediatric hematopoietic stem cell transplant recipients—Comparison of current antiviral treatment options	6
Real‐world experience of tixagevimab‐cilgavimab pre‐exposure prophylaxis in orthotopic heart transplant recipients	6
Adenovirus infection in allogeneic hematopoietic cell transplantation	6
Blastomycosis in solid organ transplant recipients—A retrospective series from southeastern Wisconsin	6
SARS‐CoV‐2 antibody responses in solid organ transplant recipients	6
Kaposi sarcoma in a child after hematopoietic stem cell transplantation: Should pre‐transplant HHV‐8 screening be considered in recipients from high prevalence areas?	6
Safety and value of pretransplant antibiotic allergy delabeling in a quaternary transplant center	6
Early post‐transplant cutaneous bacillary angiomatosis in a kidney recipient: Case report and review of the literature	5
Prevalence of carbapenemase‐producing organisms among hospitalized solid organ transplant recipients, five US hospitals, 2019–2020	5
Non‐wild‐type cryptococcosis in a child with multivisceral organ transplant who owned bird pets	5
Outcomes of SARS‐CoV‐2 infection among lung transplant recipients: A single center retrospective study	5
Safety and efficacy of Sofosbuvir and Velpatasvir in children with active hepatitis C virus infection undergoing haploidentical transplantation	5
Respiratory virus infections after allogeneic stem cell transplantation: Current understanding, knowledge gaps, and recent advances	5
Long‐term use of foscarnet is associated with an increased incidence of acute kidney injury in hematopoietic stem cell transplant patients: A retrospective observational study	5
Belatacept may result in profound and persistent loss of cytomegalovirus‐specific cell‐mediated immunity: A case report	5
Hemophagocytic syndrome triggered by donor‐transmitted toxoplasmosis as a complication in same‐donor recipients of renal transplantation: Case report and review of the literature	5
Clinical characteristics and incidence of toxoplasmosis after autologous hematopoietic stem cell transplantation: A retrospective study and literature review	5
When you need to dive in the deep end—Transplanting SARS‐CoV‐2 PCR+ recipients	5
Interleukin‐18 and tumor necrosis factor‐α are elevated in solid organ transplant recipients with possible cytomegalovirus end‐organ disease	5
Disseminated lomentosporiosis in a heart transplant recipient: Case report and review of the literature	5
COVID‐19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)‐T‐cell therapy	5
An outbreak of SARS‐CoV‐2 on a transplant unit in the early vaccination era	5
Machine learning, antimicrobial stewardship, and solid organ transplantation: Is this the future?	5
Factors associated with neutropenia post heart transplantation	5
CYP induction to reverse tacrolimus toxicity resulting from concomitant Paxlovid use	5
Incidence of cervical intraepithelial lesions and human papilloma virus infection in female renal transplant recipients	5
Fatal recurrent disseminated Lomentospora prolificans infection during autologous hematopoietic stem cell transplantation: A case report and review, and discussion on the importance of prolonge	5
Early antimicrobial prophylaxis in autologous stem cell transplant recipients: Conventional versus an absolute neutrophil count‐driven approach	5
Impact of belatacept and tacrolimus on cytomegalovirus viral load control and relapse in moderate and high‐risk cytomegalovirus serostatus kidney transplant recipients	5
Clinical impact of vancomycin‐resistant enterococci colonization in nonliver solid organ transplantation and its implications for infection control strategies: A single‐center, 10‐year retrospective s	5
Early post‐liver transplantation infections and their effect on long‐term survival	5
Plasmacytoid dendritic cell and type I interferons as possible explanation for clearance of longstanding warts during COVID‐19 in a transplant patient, reply to Erkayman et al	5
COVID‐19 in vaccinated versus unvaccinated hematologic malignancy patients	5
Solid non‐lung organs from COVID‐19 donors in seropositive or naive recipients: Where do we stand?	5
Mycetoma caused by Microsporum canis in a patient with renal transplant: A case report and review of the literature	5
Dissociation of humoral and cellular immune responses in kidney transplant recipients with EBV mucocutaneous ulcer	5
Rifabutin for treating tuberculosis in solid organ transplant recipients: A retrospective observational study and literature review	5
Mycoplasma hominis and Ureaplasma urealyticum infections in the immediate post‐lung transplant period: A case series and literature review	5
An application of the 2018 Banff Classification for BK polyomavirus‐associated nephropathy in renal transplantation	5
Conversion from cytomegalovirus universal prophylaxis with valganciclovir to the preemptive monitoring approach to manage leukopenia after kidney or pancreas transplantation	5
Ehrlichia‐induced hemophagocytic lymphohistiocytosis after autologous stem cell transplant	5
Delabeling penicillin and other antibiotic allergies in solid organ transplantation patients	5
Prediction models for carbapenem‐resistant Enterobacterales carriage at liver transplantation: A multicenter retrospective study	5
Desirability of outcome ranking and quality life measurement for antimicrobial research in organ transplantation	5
Increasing net immunosuppression after BK polyoma virus infection	5
Is creatinine an independent risk factor for predicting adverse outcomes in COVID‐19 patients?	5
Efficacy of hope: Analysis of organ quality and availability among deceased HIV‐positive donors	5
Myalgia in liver transplant recipients after receiving tixagevimab/cilgavimab for pre‐exposure prophylaxis of COVID‐19: A case series	5
Kidney transplantation in the time of COVID‐19: Dilemmas, experiences, and perspectives	5
Beta‐lactam allergies, surgical site infections, and prophylaxis in solid organ transplant recipients at a single center: A retrospective cohort study	5
Pseudotumor presentation of CMV disease: Diagnostic dilemma and association with immunomodulating therapy	5
Into the unknown: Diagnosing mysterious brain lesions	5
QuantiFERON‐cytomegalovirus to predict clinically significant cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation	5
Serologic evaluation of vaccine preventable infections and vaccination rates in kidney transplant candidates	5
Extended‐spectrum β‐lactamase‐producing and carbapenem‐resistant Enterobacterales bloodstream infection after solid organ transplantation: Recent trends in epidemiology and therapeutic approaches	5
Clinical prediction tool for extended‐spectrum beta‐lactamase‐producing enterobacterales as the etiology of a bloodstream infection in solid organ transplant recipients	5
Assessing the post hoc effectiveness of tixagevimab−cilgavimab for prevention of SARS‐CoV‐2 infections in solid organ transplant recipients	5
Cytomegalovirus‐associated pseudomembranous colitis in a kidney transplant recipient	5
Antimicrobial stewardship in solid organ transplant recipients: Current challenges and proposed metrics	5
Clinical course of severe COVID19 treated with tocilizumab and antivirals post‐allogeneic stem cell transplant with extensive chronic GVHD	5
Fatal encephalitis and Borna Disease Virus‐1 seropositivity in two kidney‐transplant patients living in the same nonendemic area	5
Evaluating antimicrobial duration for Gram‐negative bacteremia in patients with neutropenia due to hematologic malignancy or hematopoietic stem cell transplantation	5
Epidemiological and clinical study of microsporidiosis in French kidney transplant recipients from 2005 to 2019: TRANS‐SPORE registry	5